Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma.

CONCLUSIONS: Targeted therapies, lenvatinib and dabrafenib plus trametinib (for BRAF V600E mutants), may provide clinical benefit in ATC patients who are unable to participate in clinical trials, with manageable toxicities. PMID: 29161986 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research